All patients in Lipidor’s Phase III study with psoriasis candidate AKP02 have completed treatment
STOCKHOLM, Sweden – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that all patients included in the company's Phase III study with AKP02 against mild to moderate psoriasis have now been fully treated. This means that the collected data can be analysed, with results from the study expected towards the end of the third quarter of 2022.
The last patient has now received their last treatment in the observer-blind and placebo-controlled Phase III clinical trial with AKP02 cutaneous spray. The primary goal of the study is to show good therapeutic efficacy for the treatment of mild to moderate psoriasis on both the body and scalp.
The psoriasis candidate AKP02 combines calcipotriol and betamethasone dipropionate and is based on Lipidor's patented AKVANO® technology. Lipidor has chosen to compare the sprayable drug candidate AKP02 with Enstilar, which is one of the market-leading preparations for topical treatment in psoriasis. AKP02 contains the same combination of active substances as Enstilar but with a different formulation.
A positive result from the Phase lll study is the most important remaining milestone before the commercial phase according to the licence agreement signed with RELIFE S.r.l., a company in the Menarini Group, for Europe, the CIS countries and Turkey. Lipidor believes that AKP02, and the previously approved AKP01, have the potential to take a significant market share and contribute to increased patient benefit for the growing group of psoriasis patients.
"The phase III study with the psoriasis candidate AKP02 is an important study and it is gratifying that all included patients have now completed treatment. We look forward with confidence to presenting the results of the study during the third quarter of this year", says Ola Holmlund, CEO of Lipidor.
The information was provided for publication by Lipidor’s CEO on 23 August 2022 at 3.00pm CEST.